Actionable solutions to address antibody validation failures
4 affiliations
- 1School of Medical Sciences, College of Life Sciences, University of Leicester, Leicester, United Kingdom
- 2School of Health Sciences, Kristiania University of Applied Sciences, Oslo, Norway
- 3Warwick Medical School, University of Warwick, Coventry, United Kingdom
- 4School of Psychology and Vision Sciences, College of Life Sciences, University of Leicester, Leicester, United Kingdom
Abstract
The experimental use of antibodies that have not been validated for context-specific use frequently misdirects biomedical research. Experimental results that derive from the use of inadequately validated antibodies are estimated to waste over $1 billion annually in the United States alone and to consume millions of animal and human biological samples in experiments whose conclusions may be unreliable. Community validation frameworks, reporting standards, and independent characterisation initiatives have made important progress, and multi-stakeholder coordination efforts are emerging. However, the research community lacks a formally developed, consensus-based action plan that specifies what each stakeholder group should do, by when, and with what priority. We conducted a modified Delphi study with international experts representing academic researchers, scientific publishers, research funders, antibody manufacturers, and institutional research leaders to develop actionable recommendations for improving antibody validation, selection, and reporting practices. Thirty-two participants rated 33 proposed actions on effectiveness and feasibility using 9-point scales, with consensus assessed using the RAND/UCLA Appropriateness Method. Over two rounds, the panel achieved consensus on 15 items as both effective and feasible for implementation by 2030. These spanned institutional actions (training in antibody validation, integration into research integrity frameworks, support for local expertise networks), funder actions (dedicated validation budgets, grant application requirements, endorsement of community reporting standards), publisher actions (complete antibody reporting packages, clear validation standards), manufacturer actions (assignment of unique identifiers at source), and cross-stakeholder coordination (a shared roadmap for improvement). An additional 15 items were rated as effective but with uncertain feasibility, reflecting a consistent pattern in which the panel agreed on the value of proposed interventions but expressed reservations about realistic implementation timelines. One item was rejected by the panel with concerns around effectiveness and feasibility. Participants described four interconnected barriers to progress: diffuse ownership of the problem across stakeholders; market dynamics that inadequately reward antibody quality; difficulty justifying investment when returns are distributed across the research system; and coordination challenges among actors with different incentive structures. These barriers are addressable through coordinated action, and the findings complement existing technical and data-sharing initiatives by providing the structured, expert-informed policy framework to help translate awareness of the problem into concrete practice and policy changes.
Poorly validated antibodies misdirect research, wasting an estimated $1 billion a year in the United States alone and millions of animal and human samples since 2000. In this multi-stakeholder Delphi consensus study, experts across the biomedical research system agree on which practical fixes to prioritise, and who should deliver them, by 2030.
Related
- 211 A discovery-to-therapeutics platform for functional antibody targeting of complex membrane-embedded tumor antigens: validation with claudin family members
- BCell-Epitope-Prediction: A local, reproducible pipeline for multi-epitope vaccine design: integration and structural validation against a panel of PDB antigen-antibody complexes
- Validation of a high throughput fluorescent Capillary Electrophoresis Sodium Dodecyl Sulfate method for monoclonal antibody size heterogeneity assessment
- Inadequate antibody validation places substantial numbers of animal and human tissue samples at risk of waste
- Multiplex-GCN Predicts Clinically Actionable Tumor Microenvironment Subtypes in Pancreatic Cancer
BibTeX
@article{blades2026actionable,
title = {{Actionable solutions to address antibody validation failures}},
author = {Katherine Blades and Michael Biddle and Robert Froud and Eva M. Krockow and Harvinder Virk},
journal = {PLOS Biology},
year = {2026},
month = oct,
doi = {10.1371/journal.pbio.3003981},
url = {https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3003981},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Actionable solutions to address antibody validation failures
AU - Katherine Blades
AU - Michael Biddle
AU - Robert Froud
AU - Eva M. Krockow
AU - Harvinder Virk
PY - 2026
DA - 2026/10/06
JO - PLOS Biology
DO - 10.1371/journal.pbio.3003981
UR - https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3003981
AB - The experimental use of antibodies that have not been validated for context-specific use frequently misdirects biomedical research. Experimental results that derive from the use of inadequately validated antibodies are estimated to waste over $1 billion annually in the United States alone and to consume millions of animal and human biological samples in experiments whose conclusions may be unreliable. Community validation frameworks, reporting standards, and independent characterisation initiatives have made important progress, and multi-stakeholder coordination efforts are emerging. However, the research community lacks a formally developed, consensus-based action plan that specifies what each stakeholder group should do, by when, and with what priority. We conducted a modified Delphi study with international experts representing academic researchers, scientific publishers, research funders, antibody manufacturers, and institutional research leaders to develop actionable recommendations for improving antibody validation, selection, and reporting practices. Thirty-two participants rated 33 proposed actions on effectiveness and feasibility using 9-point scales, with consensus assessed using the RAND/UCLA Appropriateness Method. Over two rounds, the panel achieved consensus on 15 items as both effective and feasible for implementation by 2030. These spanned institutional actions (training in antibody validation, integration into research integrity frameworks, support for local expertise networks), funder actions (dedicated validation budgets, grant application requirements, endorsement of community reporting standards), publisher actions (complete antibody reporting packages, clear validation standards), manufacturer actions (assignment of unique identifiers at source), and cross-stakeholder coordination (a shared roadmap for improvement). An additional 15 items were rated as effective but with uncertain feasibility, reflecting a consistent pattern in which the panel agreed on the value of proposed interventions but expressed reservations about realistic implementation timelines. One item was rejected by the panel with concerns around effectiveness and feasibility. Participants described four interconnected barriers to progress: diffuse ownership of the problem across stakeholders; market dynamics that inadequately reward antibody quality; difficulty justifying investment when returns are distributed across the research system; and coordination challenges among actors with different incentive structures. These barriers are addressable through coordinated action, and the findings complement existing technical and data-sharing initiatives by providing the structured, expert-informed policy framework to help translate awareness of the problem into concrete practice and policy changes. Poorly validated antibodies misdirect research, wasting an estimated $1 billion a year in the United States alone and millions of animal and human samples since 2000. In this multi-stakeholder Delphi consensus study, experts across the biomedical research system agree on which practical fixes to prioritise, and who should deliver them, by 2030.
SN - 1545-7885
ER -